Cardea SOLO is a wearable, light (weight of three quarters), wire-free, seven-day ECG Sensor that comes complete with a PC-based, in-office Analysis Software System for the detection of adult cardiac arrhythmias, including Atrial Fibrillation (AFib).
Cardiac Insight said Cardea SOLO can trim days or weeks off ECG report turnaround time compared to using third-party ECG reporting services. It is the only in-office PC-based ECG Analysis Software cleared by the U.S. Food and Drug Administration (FDA) to produce an automated draft summary report without human intervention. The report is ready for clinician review or edits in five minutes or less. Cardea SOLO Software also provides clinicians access to, and ownership of, every heartbeat of patient data for further analysis.
The Cardea SOLO System detects and analyzes a broad range of cardiac arrhythmias that can cause disability and even death if undiagnosed and untreated. Millions of adults across the United States and Europe suffer from arrhythmia in its most common form, Atrial Fibrillation (AFib). Patients with AFib face an estimated five-times higher risk of stroke and more than double their risk of Sudden Cardiac Death.
About Cardiac Insight, Inc.
Cardiac Insight, Inc. is a leading U.S. developer of advanced body-worn digital health care information systems through its proprietary software, algorithms and devices. The company’s two flagship products are its wearable ECG Sensor and Analysis Software System, Cardea SOLO and Cardea 20/20 ECG, the only 12-lead test that incorporates the International Criteria for identification of the risk of Sudden Cardiac Arrest in young athletes. Founded in 2008, Cardiac Insight is an ISO-certified company and is based in Kirkland, Washington, USA.
Back to HCB News
